Effect of omega-3 fatty acids and simvastatin on hemostatic risk factors and postprandial hyperlipemia in patients with combined hyperlipemia.
Patients with combined hyperlipemia have lipid abnormalities associated with an increased tendency to develop atherosclerosis and thrombosis. This tendency may be accelerated during postprandial hyperlipemia. In the present double-blind parallel study, 41 patients with combined hyperlipemia and serum triacylglycerols between 2.0 and 15.0 mmol/L and serum total cholesterol >5.3 mmol/L at the end of a 3-month dietary run-in period were treated with simvastatin at 20 mg/d for at least 10 weeks; patients were then randomized into 2 groups receiving simvastatin+omega-3 fatty acids at 3.36 g/d or placebo (corn oil) for an additional 5 weeks. Hemostatic variables that have been associated with increased thrombotic tendency were evaluated with subjects in the fasting state and during postprandial hyperlipemia before and after combined treatment. Supplementation of omega-3 fatty acid reduced tissue factor pathway inhibitor antigen (P<0.05) in the fasting state, reduced the degree of postprandial hyperlipemia (P<0.005), and reduced activated factor VII concentration appearing during postprandial hyperlipemia. In conclusion, omega-3 fatty acids given in addition to simvastatin to patients with combined hyperlipemia reduced the free tissue factor pathway inhibitor fraction in the fasting state and inhibited the activation of factor VII occurring during postprandial lipemia, thus representing a potential beneficial effect on the hemostatic risk profile in this patient group.
Nordoy
A
A
Department of Medicine, University of Tromso, Tromso, Norway.
Bonaa
K H
KH
Sandset
P M
PM
Hansen
J B
JB
Nilsen
H
H
D000328:Adult; D001786:Blood Glucose / Q000378:metabolism; D004041:Dietary Fats / Q000008:administration & dosage; D004311:Double-Blind Method; D004435:Eating / Q000502:physiology; D015942:Factor VIIa / Q000378:metabolism; D015525:Fatty Acids, Omega-3 / Q000008:administration & dosage*; D005260:Female; D006487:Hemostasis / Q000187:drug effects; D006801:Humans; D006949:Hyperlipidemias / Q000097:blood / Q000150:complications / Q000188:drug therapy*; D000960:Hypolipidemic Agents / Q000008:administration & dosage*; D008074:Lipoproteins / Q000097:blood; D008297:Male; D008875:Middle Aged; D012307:Risk Factors; D019821:Simvastatin / Q000008:administration & dosage*; D013927:Thrombosis / Q000097:blood / Q000209:etiology / Q000517:prevention & control
D001786:Blood Glucose; D004041:Dietary Fats; D015525:Fatty Acids, Omega-3; D000960:Hypolipidemic Agents; D008074:Lipoproteins; C051928:lipoprotein-associated coagulation inhibitor; D019821:Simvastatin; D015942:Factor VIIa